Medtronic Gatekeeper
This article was originally published in The Gray Sheet
Executive Summary
144-patient, randomized, pivotal study will examine gastroesophageal reflux repair system's ability to improve GERD symptoms and reduce need for medication. The company's Bravo pH monitoring system will be incorporated in the trial. In May, Medtronic announced CE mark approval for Gatekeeper (1"The Gray Sheet" May 26, 2003, In Brief)...
You may also be interested in...
Medtronic Gatekeeper
European acid reflux repair system market launch will commence in coming weeks, firm says May 20 after receiving CE mark authorization. U.S. feasibility trials are completed for the endoscopic delivery system/lower esophageal sphincter prostheses, which will target an estimated 375 mil. patients worldwide. Pivotal trials with 12-month follow up will begin this summer, Medtronic says...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.